What's breaking now, across thousands of outlets.
(RTTNews) - Novartis AG (NVS, NOVN.SW) on Tuesday reported encouraging two-year results from its ongoing Phase 3 NEPTUNUS extension study of investigational drug ianalumab, showing further improvements in Sjögren's disease activity through Week 108.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
Nuclear weapons depend on elaborate safeguards intended to prevent unauthorized use while ensuring retaliation remains possible.
Hotter U.S. consumer prices lifted bets on a December Fed rate increase, with a small chance priced in for a half-point move
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
A wave of defaults and fraud among Brazil’s “shadow banks” has reportedly caught the attention of regulators. That’s according to a report Tuesday (Nov.
Key PointsKimberly-Clark has been raising its dividend every year for more than five decades.
Credit quality held steady while leverage moved toward its target midpoint.
